Skip to content

Clinical Evidence

Clinical Trial Results

The Spine Journal 22 (2022) 895–909 CLINICAL STUDY

“Intradiscal oxygen-ozone chemonucleolysis versus microdiscectomy for lumbar disc herniation radiculopathy: a non–inferiority randomized control trial”

Authorship:

Alexis Kelekis, MDa, Giuseppe Bonaldi, MDb, Alessandro Cianfoni, MDc,d, Dimitrios Filippiadis, MDa, Pietro Scarone, MDc,d, Claudio Bernucci, MDb, David M. Hooper, PhDe, Hadas Benhabib, MDf, Kieran Murphy, MDf,*, Josip Buric, MDg

Institutional Affiliations:
  • aUniversity General Hospital Attikon, Athens, Haidari 12462, Greece
  • bAzienda Ospedaliera Papa Giovanni XXIII, Bergamo, Lombardia 24127, Italy
  • cDepartment of Neuroradiology, Neurocenter of Southern Switzerland, Lugano 6900, Switzerland
  • dDepartment of Interventional and Diagnostic Neuroradiology, Inselspital University Hospital of Bern, Bern 3008, Switzerland
  • eSpinafx Medical, Vaughan, Ontario, Canada
  • fToronto Western Hospital, University Health Network, Toronto, Canada
  • gCasa di Cura San Camillo, Forte dei Marmi, Lucca 55042, Italy
The Spine Journal

Whitepaper

Filling the Therapeutic Gap in Herniated Disc Treatment: Inconsistencies in Diagnosis and Treatment Between Failed Conservative Care and Surgery.

Back pain is the #1 source of workdays lost to disability globally[1], with approximately 80% of adults experiencing a herniated disc in their lifetime[2] and an estimated prevalence of symptomatic herniated discs of 1-3% of patients[3]. The pain, loss of productivity, and related mental health deterioration resulting from chronic pain

Learn more about Triojection®